Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Research Sheds Light on Scleromyxedema, a Rare Skin Disorder

Larry Beresford  |  Issue: October 2019  |  

Larry Beresford is a medical journalist in Oakland, Calif.

References

  1. Mecoli CA, Talbot CC Jr, Fava A, et al. Clinical and molecular phenotyping in scleromyxedema pre- and post-treatment with intravenous immunoglobulin. Arthritis Care Res (Hoboken). 2019 Apr 22. [Epub ahead of print]
  2. Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: A multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013 Jul;69(1):66–72.
  3. Guarneri A, Cioni M, Rongioletti F, et al. High-dose intravenous immunoglobulin therapy for scleromyxedema: A prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1157–1160.

Related Articles

    The Mystery of IVIg

    Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.

    Fibrotic Diseases of the Retroperitoneum & Skin, & Rare Scleroderma Mimics

    SAN DIEGO—Fibrosis affects all organ systems, but isn’t always systemic sclerosis. Experts on less common forms discussed patient presentations, diagnosis and treatment at the 2017 ACR/ARHP Annual Meeting in San Diego on Nov. 6. Retroperitoneal Fibrosis Formerly called Ormond’s disease, retroperitoneal fibrosis (RPF) is usually an IgG4-related disease, but has some unique characteristics, said John…

    Case Report: Dermato-Neuro Syndrome Recurrence after a Viral Infection

    Case Report: Dermato-Neuro Syndrome Recurrence after a Viral Infection

    Scleromyxedema is a primary cutaneous mucinosis characterized by a diffuse and generalized papular skin eruption of mucinous deposits throughout the upper dermis. In addition to dermatologic manifestations, scleromyxedema may involve the cardiopulmonary, gastrointestinal, renal and nervous systems. Dermato-neuro syndrome (DNS) is a rare, severe neurologic complication of scleromyxedema.1,2 The pathogenesis of DNS is unknown, but…

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…